Join to access to all OVN content. Join for Free
"You Cannot Teach Someone How to be an MSL"
Medical Science Liaison MSL skills KOL engagement strategies MSL career tips drug launch stages

"You Cannot Teach Someone How to be an MSL"


Share This Article


Summary

In this episode, Kathleen Bailey joins Tom Caravela to explore the essential skills for Medical Science Liaisons (MSLs). They highlight the importance of communication, trust-building, and soft skills, along with strategies for real-time problem-solving and handling objections. Kathleen shares insights on managing unknown questions, the value of mentorship, and drug launch stages. She also offers tips for mastering scientific knowledge, staying updated, and the role of motivation in an MSL career. The episode wraps up with effective KOL engagement strategies and key takeaways.

Kathleen Bailey, Medical Science Liaison at Scynexis discusses what aspects can be taught to MSLs and what needs to be learned through experience.

Kathleen shares…

πŸ‘‰ What aspects of the MSL role can be taught

πŸ‘‰ What aspects of the MSL role cannot be taught and need to be learned

πŸ‘‰ Best practices for bridging the gap

πŸ‘‰ Advice on how to find success and improve performance

Click for Source
Medical Science Liaison, MSL skills, KOL engagement strategies, MSL career tips, drug launch stages

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
Over-Negotiation-How to Botch a Job Offer
Partner Avatar MSL Talk: Tom Caravela

Over-Negotiation-How to Botch a Job Offer

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, GaΓ«lle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Article
Transforming oncology: Five frontiers driving progress in cancer care
Partner Avatar iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

Explore OVN